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henotype of Human Hypertrophic
ardiomyopathy Mutation Cardiac Troponin
-Q92 in Switch On–Switch Off Bigenic Mice
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ei Wei, PHD,† Blase Carabello, MD,* A. J. Marian, MD*
ouston, Texas
OBJECTIVES The aim of this study was to establish reversibility of cardiac phenotypes in hypertrophic
cardiomyopathy (HCM) by generating bigenic mice in which expression of the mutant
transgene could be turned on and off as needed.
BACKGROUND Advances in molecular therapeutics could ultimately lead to therapies aimed at correcting the
causal mutations. However, whether cardiac phenotypes, once established, are permanent, or
could be reversed, if expression of the mutant protein is turned off, is unknown.
METHODS We generated ligand-inducible bigenic mice, turned on and off expression of cardiac troponin
T-Q92 (cTnT-Q92), responsible for human HCM, and characterized molecular, histologic,
and functional phenotypes.
RESULTS We established six lines and in dose-titration studies showed that treatment with 1,000
g/kg of mifepristone consistently switched on cTnT-Q92 expression in the heart.
Short-term (16 days) induced expression enhanced myocardial systolic function without
changing myocardial cyclic adenosine monophosphate levels. Levels of PTEN, a
regulator of cardiac function, phospho-protein kinase C--Thr538 and phosphor-
protein kinase D-Ser744-748 were reduced, whereas messenger ribonucleic acid (mRNA)
levels of NPPA, NPPB, and sarcoplasmic reticulum calcium adenine triphosphatase 2
(ATP2A2) (hypertrophic markers) and procollagen COL1A1, COL1A2, and COL3A1
were unchanged. Long-term (70 days) induced expression increased COL1A1 and
COL1A3 mRNAs levels and collagen volume fraction and reduced levels of NPPA and
NPPB. Switching off expression of the cTnT-Q92 reversed functional, molecular, and
histologic phenotypes completely.
CONCLUSIONS The initial phenotype induced by cTnT-Q92 is enhanced myocardial systolic function
followed by changes in signaling kinases and interstitial fibrosis. Established phenotypes in
HCM reverse upon turning off expression of the mutant protein. These findings provoke
pursuing specific therapies directed at correcting the underlying the genetic defect in
HCM. (J Am Coll Cardiol 2004;44:2221–30) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.005Cardiology Foundation
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cuman hypertrophic cardiomyopathy (HCM) is a genetic
isease characterized by unexplained cardiac hypertrophy,
yocyte disarray, interstitial fibrosis, and increased left
entricular ejection fraction (LVEF) (1–3). Mutations in at
east 10 different sarcomeric proteins cause HCM (2), and
hose in cardiac troponin T (cTnT) account for approxi-
ately 15% of HCM cases (2). Hypertrophic cardiomyop-
thy resulting from cTnT mutations is generally character-
zed by an increased LVEF, minimal or mild hypertrophy,
evere disarray, fibrosis, and a high incidence of sudden
ardiac death (4,5).
Elucidation of the molecular genetic basis of HCM has
hifted the focus toward elucidation of the pathogenesis of
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he National Heart, Lung, and Blood Institute, Specialized Centers of Research
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ommunity Foundation.t
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ccepted September 2, 2004.CM and developing therapies aimed at reversing or
ttenuating the evolving phenotypes and ultimately, correct-
ng the primary genetic defects. Currently, it is unknown
hether turning off expression of the mutant protein could
ead to reversal of the established phenotypes; or the
henotypes, once established, are permanent. Proving the
eversibility of the HCM phenotypes is fundamental and
rerequisite to pursuing specific molecular therapies di-
ected at correcting the underlying genetic mutation in
CM. Thus, to determine the reversibility of the evolving
henotypes and gain insight into the pathogenesis of HCM,
e generated an inducible bigenic mouse model in which
xpression of cardiac troponin T-Q92 (cTnT-Q92), known
o cause HCM in humans (4), could be switched on and off
s needed. The inducible bigenic model is based on ligand-
ependent activation of an inactive tripartite regulatory
rotein containing the ligand-binding domain of a trun-
ated human progesterone receptor (PR) that upon activa-
ion with mifepristone binds to the deoxyribonucleic acid
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Inducible Transgenic Troponin T Mice December 7, 2004:2221–30DNA) sequences in the target transgene and induces
xpression of the target gene (6).
ETHODS
he switch on–switch off (inducible) cTnT-Q92 bigenic
ice. The Animal Subjects Committee of Baylor College
f Medicine approved the experiments. The regulator is a
ripartite protein composed of the ligand-binding domain of
C-terminal truncated (deletion of 42-amino acid) human
R, the DNA-binding domain of yeast GAL4 protein, and
he transcription activation domain of the p65 subunit of
uman nuclear factor kappa B transcription factor. It is
nactive in its native state, because the modified ligand-
inding domain lacks the ability to respond to progestins
ut responds to synthetic anti-progesterone mifepristone
RU486) (7). The target transgene is comprised of four
laced in tandem 17-bp (CGGAGTACTGTCCTCCG)
AL4 upstream activating sequences (UAS) and TATA
ox positioned 5= to a mutant cTnT-Q92 complementary
eoxyribonucleic acid (cDNA). Expression of the target
ransgene could be turned on and off by adding or with-
rawing mifepristone. The -myosin heavy chain (MyHC)
romoter affords cardiac-restricted expression of the regu-
ator protein and consequently, that of the cTnT-Q92 (Fig.
A).
The -MyHC promoter (clone 26) was a kind gift from
r. Jeffery Robbins (University of Cincinnati), and the
AP-CMV-GLp65-SV and p17x4-TATA-CAT plasmids
ere generous gifts from Dr. Sophia Y. Tsai (Baylor
ollege of Medicine). To clone the regulator transgene, the
Lp65 fragment containing the coding sequences for the
ripartite regulator protein was excised from PAP-CMV-
Lp65-SV at the unique Asp718 and BamH1 restriction
ites, blunt ended and ligated to the blunt-ended SalI and
indIII cloning sites of clone 26, downstream to the
Abbreviations and Acronyms
ANOVA  analysis of variance
ATPase  adenosine triphosphatase
cAMP  cyclic adenosine monophosphate
cDNA  complementary deoxyribonucleic acid
cTnT  cardiac troponin T
cTnT-Q92  cardiac troponin T-Q92
CVF  collagen volume fraction
HCM  hypertrophic cardiomyopathy
LV  left ventricular
LVEF  left ventricular ejection fraction
mRNA  messenger ribonucleic acid
MyHC  myosin heavy chain
NTG  non-transgenic
PCR  polymerase chain reaction
PKC  protein kinase C
PR  progesterone receptor
RT-PCR  reverse transcription-polymerase chain
reaction
UAS  upstream activating sequences-MyHC promoter (Fig. 1A). To clone the target trans- tene, a previously described full-length (1.1 kb) human
TnT-Q92 cDNA (8) was released from the pSP73/cTnT-
92 clone and inserted at XhoI and KpnI sites, replacing the
AT sequences in the p17x4-TATA-CAT clone. The
orrect orientations and the sequence of the transgenes were
erified by direct sequencing. The regulator transgene (7
b) was released from the vector by digesting the clone at
he encompassing Not1 sites and the target transgene by
igesting the clone at HindIII and KpnI sites (2 kb).
ransgenes were purified from the gel and injected into
ertilized mouse zygotes (FVB/N), and the pups were
creened by polymerase chain reaction (PCR) for the
egulator and target transgenes and for the  casein, as an
nternal control.
witch on and off protocol. Mifepristone (Biomol, Ply-
outh Meeting, Pennsylvania) was initially dissolved in
imethyl sulfoxide at a concentration of 40 mg/ml, and the
orking solution was prepared in sesame oil at a concen-
ration of 1 mg/ml. To induce target gene expression,
ose-titration and time-course experiments were performed
nd mifepristone was injected intraperitoneally (n 5 to 12
dult mice per group) at three dosages of 300, 500, and
,000 g/kg/day for 2, 4, 8, or 16 days (short-term) or 70
ays (long-term). To switch off expression of the transgene,
ifepristone was discontinued for at least 16 days, which is
onger than five half-lives of cTnT in the heart (9) and for
0 days in long-term experiments. Parallel experiments were
erformed in non-transgenic (NTG) littermates injected
ith mifepristone and in bigenic mice injected with a
lacebo (sesame oil). Expression of the target transgene was
etermined by reverse transcription-polymerase chain reac-
ion (RT-PCR) and immunoblotting after switching on or
ff expression of the transgene at the above time points.
hort-term (2, 4, 8, and 16 days) induction of expression of
TnT-Q92 transgene was achieved through daily intraperi-
oneal injections. To induce long-term expression of cTnT-
92 transgene, mifepristone controlled-released pellets (In-
ovative Research of America, Sarasota, Florida) were
repared to deliver 1,000 g/kg/day and implanted
ubcutaneously.
T-PCR, real-time quantitative PCR, and immunoblot-
ing. The RT-PCR and immunoblotting were performed
sing transgene-specific oligonucleotide primers and mono-
lonal anti-troponin T antibody 2D10 (Research Diagnos-
ics Inc., Flanders, New Jersey), respectively, as described
8). Relative expression levels of the transgene and endog-
nous cTnT messenger ribonucleic acids (mRNAs) were
etermined by RT-PCR using primers (forward
=TTCATGCCCAACTTGGTGCC and reverse
=CTCTCTTCAGACAGGCGGTTC). A 260-bp of en-
ogenous and transgene cTnT mRNAs was amplified and
igested with 10 units of BstU1 restriction enzyme, which
igests the endogenous (mouse) but not the transgene
human) cTnT into two fragments of 184 and 76 bp.
Expression levels of molecular markers of cardiac hyper-
rophy (A-type natriuretic peptide [NPPA], B-type natri-
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arcoplasmic reticulum calcium adenosine triphosphatase
ATPase) 2a [SERCA2a or ATP2A2]), cardiac fibrosis
procollagens COL1(1), COL1(2), and COL3(1)
RNAs (COL1A1, COL1A2, and COL3A1, respectively)],
nd glyceraldehyde-3-phosphate dehydrogenase were deter-
ined by real-time quantitative RT-PCR using specific
aqman probes and primers in a 7900HT SDS unit
Applied Biosystems, Inc., Foster City, California).
Expression levels of selected phosphorylated and total
ignaling kinases, implicated in affecting cardiac structure
nd function, were detected using 20 g of cardiac protein
igure 1. Schematic structure of the transgenes and documentation of trans
he regulator is an inactive tripartite protein that is expressed specifically
rotein and induces conformational changes that expose the DNA binding
ransgene, juxtaposing the transcription activation domain of p65 to a
ubsequent transcription of the downstream sequences (cTnT-Q92 transge
s pGEM. TheGLp65 and cTnT denote positive controls for the regu
NA from F2 mice screened for carrying the regulator (forward primer
TCTCGCCTAGTTG) and target (forward 5=GAGCAGGAAGAAG
ransgenes. The lower band in each lane identifies an approximately 500-bp
forward 5= GATGTGCTCCAGGCTAAAGTT and reverse 5=AGAAA
nd the target transgenes are identified by *. (C) Detection of expression
uman cTnT and human heart mRNA are included as positive controls an
s negative controls. The  and  denote RT-PCR with and without sup
ine treated with placebo, three bigenic lines treated with mifepristone (1
ncluded. The presence of 760 bp PCR products (forward: 5=GGTTA
GCTGTT) identifies expression of the induced cTnT-Q92 in thre
ATA-cTnT-92 monogenic mouse confirms the absence of background e
igenic mice. Cardiac protein extract from a human heart is included as p
onogenic mice and bigenic mouse treated with placebo (each 20 g) ar
xpression of transgene protein in the heart of a bigenic mouse treated
onoclonal antibody 2D10. The mini-panels to the right indicate switchin
ow shows expression of total cTnT (endogenous and transgene), detect
xford). The lower panel shows expression of sarcomeric -actin (Biomextracts and phospho-specific and pan-specific antibodies, vs described (10). Specific information about antibodies is
vailable upon request.
-mode, two-dimensional, and Doppler echocardio-
raphy. Echocardiography was performed before and after
witching on and off expression of the transgene at each
ose and time point. Mice were anesthetized with intraperi-
oneal injection of anesthetics (avertin 0.2 ml/10 g body
eight, intraperitoneal injection of a 1.25% solution in the
ong-term experiments), and trans-thoracic echocardiogra-
hy was performed using an Acuson Sequoia Cardiac
ystem equipped with a 15-MHz linear transducer (Acuson
o., Mountain View, California) in accordance with con-
expression. (A) Schematic diagrams of the regulator and target transgenes.
heart. Mifepristone binds to the ligand-binding domain of the tripartite
in of the protein. The latter domain binds to GAL4 sequences in the target
al TATA box (TCTAGAGGGTATATAATGGATCCGGAT) and
B) Polymerase chain reaction screening of bigenic mice: DNA size marker
nd the target transgenes, respectively. The remainder of the wells represent
GCTCCTCTGCCAGTGTTGATAT and reverse 5=AGAAGTTGC-
CTGTTGA and reverse 5=GGTCGAACTTCTCTGCCTCCAAG)
ent of the mouse  casein gene used as an internal control for DNA quality
AATGTTGTGGAGT). Three bigenic mice carrying both the regulatory
ucible cTnT-Q92 mRNA in bigenic mice by RT-PCR. The cDNA for
iac mRNAs from non-transgenic (NTG) and monogenic TATA-cDNA
pt reverse transcriptase in the reaction. Cardiac mRNA from one bigenic
s), and one bigenic line 16 days after discontinuation of mifepristone are
TTGATCCTGATTGCC and reverse: 5=GGAGCAGGAAGAAGC-
es of bigenic mice. The absence of RT-PCR product in the target
sion of cTnT-Q92. (D) Expression of induced cTnT-Q92 in the heart of
e control. Cardiac proteins from NTG, GLp65, and TATA-cTnT-Q92
uded as negative controls. The presence of a 37-kDa band identifies the
mifepristone, which was detected using human specific anti-troponin T
xpression of cTnT-Q92 after discontinuation of mifepristone. The middle
ing pan-specific anti-troponin T antibody JLT-12 (Serotec, Kidlington,
nc., Foster City, California), a marker for loading condition.gene
in the
doma
minim
ne). (
lator a
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Inducible Transgenic Troponin T Mice December 7, 2004:2221–30ere measured in at least three consecutive cardiac cycles by
n investigator totally unaware of the genotypes or the
reatment groups.
istologic studies. The extent of cardiac myocyte disarray
nd interstitial fibrosis were quantified as published (10,12).
ercentage of myocardium showing disarray was deter-
ined in a semiquantitative manner in 12 fields per section
nd 10 sections per mouse. Similarly, collagen volume
raction (CVF) was calculated using quantitative automated
lanimetry in 12 fields per section and 10 sections per
ouse. Myocyte cross-sectional area was determined by
uantitative indirect immunofluorescence in approximately
,500 myocytes per group, as published (10,12). All histo-
ogic quantifications were performed by an examiner who
ad no knowledge of group assignment.
yocardial cyclic adenosine monophosphate (cAMP)
evels. Because cAMP is a major mediator of myocardial
ontractile function, we measured total myocardial cAMP
evels by enzyme immunoassay according to the instructions
f the manufacturer (Amersham Biosciences, Piscataway,
ew Jersey). In brief, 100-mg aliquots of ventricular myo-
ardium (n  4 to 8 mice per group) were homogenized
n Hanks’ balanced salt solution with 5-mM ethylenedi-
minetetraacetic acid without calcium and magnesium and
entrifuged at 1,000 g at 4°C for 15 min. The homogenates
ere subjected to ion-exchange chromatography using col-
mns containing anion exchange silica sorbents followed by
nalyte elution with acidified methanol. The eluted samples
ere added to an assay buffer containing rabbit anti-cAMP
ntibody in 0.05-M acetate, 0.02% (w/v) bovine serum
lbumin and mixed thoroughly. Then, an equal volume of
AMP-horseradish peroxidase conjugate in 0.05-M acetate
uffer, pH 5.8 was added to each reaction and washed with
.01-M phosphate buffer pH 7.5 containing 0.05% (v/v)
ween 20. The mixtures were added to microplates coated
ith a donkey anti-rabbit immunoglobulin G antibody,
ncubated at 4°C for 60 min. After washing, the enzyme
ubstrate was added to the wells, and the reactions were
erminated after 1 h of incubation at room temperature with
.0 M sulfuric acid. The optical density was determined
mmediately in a plate reader at 450 nm.
tatistical methods. Differences between the baseline and
ollow-up values in each group were compared by paired t
est. Differences in variables among multiple groups, such as
TG, placebo, and mifepristone groups, were compared by
nalysis of variance (ANOVA). Similarly, differences in the
henotype at different experimental points, that is, before
nd after switching on and off expression of the transgene,
n each group of mice were compared by repeated measures
NOVA. Homogeneity of the variances was tested by
artlett’s test. Variables with unequal standard deviation
LVEF by two-dimensional echocardiography, deceleration
ime of mitral inflow E velocities, and myocyte disarray)
ere compared by the non-parametric Kruskal-Wallis test.
initab software (version 14) was used for the statisticalnalysis. sESULTS
igenic mice. Three lines of regulator (-MyHC/GLp65-
AL4-PR) and seven lines of target (4xGAL4UAS-
ATA-cTnT-Q92) transgenic mice were generated. The
arget transgenic lines were tested for background expres-
ion of the cTnT-Q92, after confirmation of the absence of
ackground leak, mated to the regulator transgenic mice,
nd six lines of bigenic mice were established. Monogenic
nd bigenic mice were identified by PCR using transgene-
pecific oligonucleotide primers (Fig. 1B). Mice from three
ines, backcrossed at least five times, were used in these
xperiments.
witching on and off cTnT-Q92 mRNA and protein
xpression. Expression of the transgene mRNA and pro-
ein was detected consistently after daily administration of
ifepristone at 1,000 g/kg/day for 16 days. Shorter
urations or lower doses of administration of mifepristone
id not consistently induce expression of the transgene. The
esults of RT-PCR (in three lines, Fig. 1C) and immuno-
lotting (in one line, Fig. 1C) confirmed expression of the
TnT-Q92 mRNA and protein, respectively. No significant
TnT-Q92 expression was detected in bigenic mice injected
ith a placebo or in the target monogenic mice. The relative
xpression level of the induced transgene cTnT was low in
ll lines and comprised 10% of the total cTnT mRNA in
he heart. Transgene protein and mRNA were not detected
6 days after discontinuation of mifepristone (Fig. 1D).
In the long-term study, 2 of 9 bigenic mice died 3 and 9
ays after mifepristone injection, in contrast to 0 of 11
TG mice injected with mifepristone or 0 of 9 bigenic mice
njected with the placebo. Baseline echocardiographic indi-
es were unremarkable in two mice that died after induced
ransgene expression. Because these mice were found dead,
o histologic or molecular studies were performed.
yocardial systolic and diastolic function. Echocardio-
raphic indices of myocardial function were compared at the
aseline before injection of mifepristone; 16 and 70 days
fter induction of expression of the cTnT-Q92 in the heart;
nd 16 days and 70 days after discontinuation of mifepris-
one administration. The results were remarkable for a
maller left ventricular (LV) end-systolic diameter, in-
reased LV fractional shortening, LVEF, velocity of cir-
umferential fiber shortening, and maximum aortic flow
elocity in induced state at both time points (16 and 70
ays) compared with the baseline values. There were no
ignificant differences in the LV wall thickness, end-
iastolic diameter, or mitral inflow early (E), late (A), and
/A. However, deceleration time of E velocity was pro-
onged in the bigenic mice injected with mifepristone. Table
shows the summary of echocardiographic data at the
aseline, 16 days after induced gene expression, and 16 days
fter discontinuation of mifepristone injection (data for 70
ays induced expression were largely similar, except the
ean heart rate was 462  71 beats/min, and are nothown). Discontinuation of mifepristone led to reversal of
Table 1. Echocardiographic Phenotype in Bigenic Mice After Switching On and Off Expression of cTnT-Q92
NTG Bigenic Placebo Bigenic Mifepristone
p*
Baseline
(n  7)
On Mife
(n  5) p
Baseline
(n  7)
On Placebo
(n  5) p
Baseline
(n  14)
On Mife
(n  11)
Off Mife
(n  4) p
Gender (M/F) 5/2 3/2 — 4/3 2/3 — 7/7 5/6 2/2 — —
Age (days) 132 62 148  61 — 121  29 137 28 — 112  32 128  36 156  34 — —
HR (beats/min) 380 36 393  24 0.504 384  30 358 32 0.756 369 38 373  43 382  48 0.148 0.620
Body weight (g) 27  5 24  3 0.262 28  5 29  4 0.500 28  4 29  5 29  2 0.637 1.0
ST (mm) 0.77 0.09 0.70 0.10 0.244 0.72 0.05 0.77 0.07 0.162 0.72 0.05 0.73 0.1 0.78  0.05 0.369 0.396
PWT (mm) 0.77 0.1 0.70 0.01 0.244 0.71 0.06 0.72 0.04 0.699 0.73 0.09 0.74 0.07 0.78  0.05 0.538 0.529
LVEDD (mm) 4.1 0.3 4.1  0.06 0.882 4.1 0.3 4.4 0.4 0.158 4.3 0.4 4.2  0.4 4.4  0.4 0.746 0.624
LVESD (mm) 2.9 0.3 2.8  0.1 0.612 2.7  0.3 3.0 0.3 0.264 2.9 0.4 2.5  0.3 2.9  0.2 0.050 0.008
FS (%) 28.8 3.9 29.9 2.2 0.452 35.4 4.3 33.3 2.0 0.466 31.1 3.3 40.0 3.7 33.9  5.0 <0.001 <0.001
LVEF-M mode (%) 60.2 7.2 63.7 3.8 0.446 67.8 3.7 68.6 3.7 0.515 65.6 5.3 77.3 3.5 69.2  5.8 <0.001 <0.001
LVEF-2D (%) 47.4 4.5 46.0 3.3 0.365 47.7 6.1 51.4 5.7 0.141 51.2 6.9 62.8 3.2 49.4  3.8† <0.001 <0.001
Vcf (c/s) 4.6 0.83 5.0 0.71 0.557 5.6 0.66 5.7 0.06 0.539 5.3 1.0 6.3  0.60 4.8  0.40 0.004 0.008
Ao Vmax (m/s) 1.1 0.09 1.1 0.04 0.804 1.1 0.16 1.0 0.13 0.204 1.1 0.13 1.2 0.11 0.98  0.07 0.001 0.006
E (m/s) 0.90 0.08 0.97 0.1 0.253 0.97 0.08 1.0 0.10 0.670 0.90 0.10 0.98 0.17 0.82  0.09 0.124 0.812
E/A 2.4 0.7 2.7  0.8 0.705 2.2  0.2 2.2 0.6 0.639 2.3 0.7 3.1  1.9 2.3  0.3 0.425 0.128
DT (ms) 35.1 2.8 32.3 2.1 0.169 32.7 4.2 35.2 4.1 0.234 33.9 3.1 39.2 1.6 33.0  1.2† 0.007 0.028
LVM (mg) 114 29 110  5 0.374 113  21 114 11 0.951 114 20 116  19 130  17 0.292 0.076
LVM/BW (mg/g) 4.1 0.4 4.4  0.09 0.237 4.0 0.4 3.7 0.3 0.138 4.0 0.4 4.0  0.9 4.6  0.5 0.177 0.340
HW/BW (mg/g) — 4.4 0.5 — — 4.7  0.3 — — 4.9  0.3 4.5  0.3 0.126 0.237
Bold face p values indicate statistically significant p values. The p values reflect comparisons between the baseline and follow-up data in each group (paired t test). The p* values reflect comparisons of values in bigenic-placebo and
bigenic-mifepristone groups. †Unequal SD among the groups (p  0.05) and analysis by Kruskal-Wallis test. The differences among the NTG (on mifepristone), Bigenic on Placebo, and Bigenic on Mifepristone groups were statistically
significant (ANOVA) for LVESD (F  6.5, p  0.008), FS (F  20.8, p  0.001), LVEF (F  27.2, p  0.001), Vcf (F  9.5, p  0.002), Ao Vmax (F  5.6, p  0.013), and DT (F  14.4, p  0.0002).
Ao Vmax  aortic maximum velocity; c/s  circumference per second; DT  deceleration time; E  mitral valve inflow E velocity; E/A  mitral valve inflow E/A ratio; FS  fractional shortening; HR  heart rate; HW/BW 
heart weight/body weight ratio; LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular ejection fraction; LVESD  left ventricular end-systolic diameter; LVM  left ventricular mass; LVM/BW  left ventricular
mass/body weight ratio; Mife  mifepristone; NTG  non-transgenic; PWT  posterior wall thickness; ST  septal thickness; 2D  two-dimensional; Vcf  velocity of circumferential fiber shortening.
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Inducible Transgenic Troponin T Mice December 7, 2004:2221–30he echocardiographic phenotypes. Representative M-mode
chocardiographic views of the left ventricle in bigenic mice
efore and after switching on and off expression of the
TnT-Q92 transgene are shown in Figure 2. There were no
iscernible differences in induced cardiac phenotypes among
he three lines used in these experiments. There were no
ignificant changes in other echocardiographic indices. In
ddition, echocardiographic indices of cardiac systolic func-
ion were not significantly different among NTG, mono-
enic target (TATA-cTnT-Q92), and monogenic regulator
GLp65) mice. The LV fractional shortening, LVEF, and
elocity of circumferential fiber shortening values were 28.8
3.9, 60.2  7.2, and 4.6  0.83 in NTG mice (Table 1);
7.6  2.01, 58.3  8.2, and 4.3  0.74 in monogenic
arget mice; and 29.3 2.45, 61.5 6.7, and 4.7 0.54 in
onogenic regulator mice. Injection of mifepristone, at
,000 g/kg/day, to NTG mice alone had no significant
ffects on LV systolic function or other echocardiographic
ndices (Table 1).
yocardial cAMP levels. To determine whether in-
reased cAMP levels were responsible for the enhanced
yocardial systolic function, we measured total myocardial
AMP levels in the experimental groups. There were no
ignificant differences in myocardial cAMP levels among
he experimental groups (NTG: 15.9  3.9 fmol/g; target
ransgenic: 17.5  3.0 fmol/g; regulator transgenic: 17.0 
igure 2. Representative M-mode echocardiographic views of the left vent
re shown before and after switching on and off expression of the cTnT
ractional shortening (EDD, ESD, and FS, respectively) are depicted und.3 fmol/g; bigenic placebo: 16.3  3.4 fmol/g; bigenic rifepristone on: 13.5  4.8 fmol/g; bigenic mifepristone
ff: 13.1  1.5 fmol/g, F  1.70, p  0.162).
evels of activated signaling kinases. To determine
hether induced expression of cTnT-Q92 also led to
hanges in expression of activated signaling molecules, we
ssayed for levels of selected signaling kinases, implicated in
ardiac function, by immunoblotting using phospho-
pecific antibodies. The results, partially shown in Figure 3,
ere notable for a significant reduction in the expression
evel of PTEN and to a lesser extent, in levels of p-protein
inase C (PKC)--Threonine 538 and p-protein kinase D
PKD)-Serine 744-748, when transgene was turned on for
6 days. There were no significant changes in levels of
I3K-p110-, , ; and p85 or p-PKC--Serine 643,
-protein kinase A (PKA), p42/p44 mitogen-activated pro-
ein kinases, glycogen synthase kinase 3, calcineurin, or
hosphorylated phospholamban. Discontinuation of mife-
ristone led to normalization of the activated signaling
olecules. There were no statistically significant changes in
he expression levels of selected signaling kinases after
horter (2, 4, and 8 days) or longer (70 days) duration of
nduction of expression of cTnT-Q92 in the heart. To
etermine whether changes in the expression levels of
ignaling kinases were independent of administration of
ifepristone, NTG mice were injected with 1,000 g/kg/
ay of mifepristone (n  4) and immunoblotting was
the treatment (A) and placebo (B) groups. In each panel, M-mode views
transgene. Left ventricular end-diastolic and end-systolic diameters and
h panel.ricle in
-Q92
er eacepeated. Mifepristone injection alone did not induce sig-
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December 7, 2004:2221–30 Inducible Transgenic Troponin T Miceificant changes in levels of p-PKC--Threonine 538 and
-PKD Serine 744-748 or PTEN in the heart.
yocardial levels of molecular markers of hypertrophy
nd fibrosis. Expression levels of NPPA, NPPB, ACTA1,
TP2A2, COL1A1, COL1A2, and COL3A1 were deter-
ined using real-time quantitative RT-PCR, 16 and 70
ays after induction of expression of cTnT-Q92 and after
witching off expression of the transgene. After 16 days of
nduced expression, myocardial levels of molecular markers
f hypertrophy and fibrosis were largely unchanged with the
xception of a modest decrease in ATP2A2 levels (data not
hown). However, long-term (70 days) induced expression
f cTnT-Q92 led to significant reductions in expression
evels of NPPA and NPPB without a significant change in
TP2A2 levels (Fig. 4A). Furthermore, expression levels of
OL1A1 and COL1A3, encoding the predominant cardiac
ollagen, were increased significantly, whereas expression
evel of COL1A2 was largely unchanged (Fig. 4A).
istologic phenotype. To detect whether induction of
xpression of cTnT-Q92 was associated with morphologic
r histologic phenotypes characteristics of human HCM,
e determined heart weight, heart weight/body weight
atio, LV weight/body weight ratio, myocyte cross-sectional
rea, number of myocytes per microscopic fields, % CVF,
igure 3. Expression of selected signaling molecules after short-term indu
f the major components of PI3K pathway: each lane represents one expe
ifepristone (Mife On) at 1,000 g/kg/day for 16 days. Mife Off indicate
howing expression levels of selected phosphorylated PKC isoforms; the b
oading condition. Groups are as indicated for panel A. (C, D, and E) Qua
values are shown for the entire groups. All p values were 0.05 when le
heir corresponding levels in other experimental groups (ANOVA).nd the extent of myocyte disarray. Short-term induced fxpression of the cTnT-Q92 did not lead to discernible
hanges in histologic or morphologic phenotypes, as no
ignificant differences in morphometric histologic indices
ere detected among NTG alone, NTG injected with
ifepristone, target and regulator monogenic mice, and
igenic mice in the placebo and mifepristone groups.
owever, as shown in Figure 4B, induced expression of
TnT-Q92 for 70 days led to a 1.45-fold increase in CVF,
n accord with the observed increased expression of the
rocollagen mRNAs. Turning off expression of cTnT-Q92
ed to normalization of CVF (bigenic placebo: 2.9  0.65;
witch on: 4.2  1.0; switch off: 2.0  0.24; F  12.4, p 
.001; p  0.05 between placebo and switch on). Long-
erm treatment of NTG mice with mifepristone had no
ignificant effect on CVF (2.5  0.66 vs. 2.8  0.73, n 
, p  0.538). With regard to indices of hypertrophy,
either heart weight/body weight ratio, echocardiographic
ndices, nor myocyte cross-sectional area was significantly
ifferent among the experimental groups. Myocyte disarray
omprised 6.3  3.6% of the myocardium in the bigenic
ice induced with mifepristone for 70 days, whereas it was
.8  2.6% in NTG mice (T  2.02, p  0.08) and 5.0 
.7% in bigenic mice after turning off expression of the
ransgene (Kruskal-Wallis test: H  2.92, degrees of
pression of cTnT-Q92 in bigenic mice. (A) Immunoblots showing levels
tal group, as labeled. Bigenic mice were injected with either a placebo or
enic mice after withdrawal of mifepristone for 16 days. (B) Immunoblots
panel shows expression levels of sarcomeric actin, used as a control for
ive levels of PTEN, p-PKC--T538, and p-PKD-S744-748. The F and
f PTEN, p-PKC--T538, and p-PKD-S744-748 were compared withced ex
rimen
s big
ottom
ntitat
vels oreedom  2, p  0.232).
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Inducible Transgenic Troponin T Mice December 7, 2004:2221–30igure 4. Induction of expression of markers of hypertrophy and fibrosis and histologic phenotypes. (A) Relative expression levels of marker of hypertrophy
cardiac load) and fibrosis. The upper panels show relative expression levels of A-type natriuretic peptide (NPPA), B-type natriuretic peptide (NPPB), and
arcoplasmic reticulum calcium ATPase 2a (SERCA2a or ATP2A2) in the heart in the experimental groups, determined by real-time quantitative RT-PCR.
ll values were corrected for levels of mRNA in the NTG control group. Labels are as follows: 1: non-transgenic littermates (NTG); 2: target transgene
nly (TATA-cTnT-Q92); 3: regulator transgene only (GLp65); 4: bigenic in the placebo group; 5: bigenic mice on mifepristone group (16 days); and 6:
igenic mice off mifepristone for 16 days. All p values were 0.05 for comparisons of NPPA and NPPA levels between bigenic mice on mifepristone versus
ach of the other groups (t test) and among all groups (ANOVA). The lower panels show relative expression levels of cardiac collagens, namely COL1A1,
OL1A1, and COL3A1 in the experimental groups. Labels are as above. All p values are 0.001 and 0.01 in comparing COL1A1 and COL3A1 levels,
espectively, between bigenic mice on mifepristone versus each of the other groups (t test) and among all groups (ANOVA). (B) Histologic phenotypes
n the NTG and bigenic mice in the placebo and mifepristone groups. The upper panels represent Sirius Red staining of thin myocardial sections used
o determine CVF. The values under each micrograph indicate mean  SD of CVF in the corresponding group. The lower panels show
mmunofluorescence micrographs stained with anti-laminin B monoclonal antibody and a rhodamine-conjugate secondary antibody to delineate theyocyte boundaries. Values under each panel indicate mean  SD pixels per myocyte in each group.
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December 7, 2004:2221–30 Inducible Transgenic Troponin T MiceISCUSSION
e describe a switch on–switch off bigenic mouse model in
hich expression of the mutant sarcomeric protein cTnT-
92, responsible for human HCM (4), was turned on and
ff by administering and withdrawing mifepristone, the
ctivating ligand for the otherwise inactive regulatory pro-
ein. Short-term induced expression of the mutant cTnT-
92 enhanced myocardial systolic function, a characteristic
henotype of HCM, independent of myocardial cAMP
evels and in the absence of histologic or molecular pheno-
ypes of hypertrophy, disarray, or fibrosis. Enhanced myo-
ardial contractile performance was associated with reduced
evels of selected active signaling kinases, implicated in
egulating cardiac function. Long-term induced expression
f cTnT-Q92 led to increased expression of procollagen
enes and interstitial fibrosis, whereas levels of the molec-
lar markers of hypertrophy were reduced. The induced
henotypes, namely, interstitial fibrosis, increased expres-
ion of procollagen genes and signaling kinases, and en-
anced cardiac systolic function were completely reversed
pon switching off expression of cTnT-Q92. These results,
n a genetic animal model of human HCM mutation,
stablish the reversibility of HCM phenotypes, a prerequi-
ite in designing future therapies targeted at correcting the
nderlying genetic mutations. The results also identify the
rimary defect conferred by cTnT-Q92 as enhanced myo-
ardial systolic function, independent of myocardial cAMP
evels. Thus, the potential utility of the switch on–switch off
igenic mouse model is at least twofold: first, to establish
he reversibility of the cardiac phenotypes induced by HCM
utations; and second, to identify the initial defects con-
erred by the mutations through delineation of the sequence
nd pathogenesis of ensuing functional, molecular, histo-
ogic, and morphologic phenotypes in HCM.
The finding of reversal and normalization of interstitial
brosis after switching off expression of the mutant troponin
was confirmed by two complementary methods of real-
ime RT-PCR analysis of expression of major procollagen
enes in the heart as well as by quantitative morphometric
nalysis of collagen protein in myocardial sections stained
ith collagen-specific dye. Reversal and normalization of
nterstitial fibrosis in the heart has potential clinical impli-
ations, because interstitial fibrosis is a potential risk factor
or sudden cardiac death in humans with HCM (13). In
ontrast to interstitial fibrosis, however, cardiac hypertrophy
as absent in the bigenic cTnT-Q92 mice, as was also the
ase in the conventional transgenic cTnT-Q92 mice (8,14).
otably, humans with HCM caused by cTnT-Q92 usually
xhibit mild or minimal hypertrophy (15). The absence of
iscernible hypertrophy in the bigenic mice or even the
resence of smaller myocyte and heart size in the conven-
ional cTnT-Q92 mice (11,14) could simply reflect the
nhanced cardiac performance, which affords the heart the
bility to handle the normal load at a smaller cardiac mass.
n accord with the foregoing, expression levels of markers of iardiac mass, namely NPPA and NPPB, were reduced
ignificantly after long-term induced expression of cTnT-
92. Regarding myocyte disarray, it was increased modestly
n the bigenic mice following long-term induced expression.
owever, changes were of borderline statistical significance.
herefore, it remains to be determined whether switching
ff expression of the mutant protein could also lead to
eversal of hypertrophy and disarray, as we have shown
reviously through pharmacologic interventions in geneti-
ally engineered animal models (10,12).
The molecular basis of enhanced myocardial contractile
erformance after induction of expression of cTnT-Q92
as not discerned, suffice that it was independent of
yocardial cAMP levels or phosphorylation of phospho-
amban, or injection of mifepristone. We have shown
reviously that myofibrils isolated from the hearts of the
onventional cTnT-Q92 transgenic mice exhibited en-
anced calcium sensitivity of tension generation, evidenced
y a higher values of half-maximally activating log of the
olar free Ca2 concentration (pCa50) (16). The latter, in
onjunction with the results of studies in skinned fibers
solated from rabbit and pig hearts showing enhanced Ca2
ensitivity (17,18), are likely to explain the observed en-
anced cardiac systolic function in our bigenic mice in the
nduced state. In addition to enhanced Ca2 sensitivity,
ther mechanisms, including changes in signaling mole-
ules, as observed after induced expression of cTnT-Q92,
ould also affect cardiac function. Regarding the potential
mpact of signaling molecules, our study was limited to
nalysis of a limited number of signaling molecules, impli-
ated in regulating cardiac structure and function, and was
ot comprehensive. Nonetheless, a significant change in the
xpression level of tumor suppressor PTEN, implicated in
egulating cardiac function (19), was detected. The PTEN,
n addition to affecting cardiac function, also plays an
ssential role in proper cell adhesion, alignment, and mi-
ration (20,21). Thus, given the essential role of PTEN in
ellular attachment and alignment, reduced expression of
TEN could be involved in the subsequent evolution of
yocyte disarray in HCM. The molecular mechanisms that
egulate expression and activation of PTEN, p-PKC--
hreonine 538, and p-PKD-Serine 744–748 in the heart
emain unknown. We showed that reduction in the expres-
ion levels of selected signaling molecules was independent
f mifepristone administration. The role of changes in the
ctivation state of selected signaling kinases, noted earlier,
n the pathogenesis of cardiac phenotypes in HCM merits
dditional investigations.
The findings of the present study are restricted to the
TnT-Q92 mutation. We note that the initial impetus and
he ensuing early and intermediary phenotypes, imparted by
he mutant sarcomeric proteins are likely to be diverse and
ary according to the topography of the causal mutations
nd genes. The bulk of experimental data implicates en-
anced myofibrillar Ca2 sensitivity as the initial defectmparted by mutations in the cTnT (16–18). However,
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Inducible Transgenic Troponin T Mice December 7, 2004:2221–30ith regard to mutations in the -MyHC and other genes,
educed myofibrillar and myocardial contractile perfor-
ance and/or reduced ATPase activity have emerged as the
rime candidates as the initial defects (reviewed in reference
). The complexity of the pathogenesis of HCM pheno-
ypes is further elucidated by the divergence of phenotypic
xpression of mutations in the same causal gene, which lead
o morphologically contrasting phenotypes of hypertrophic,
ilated, and restrictive cardiomyopathies (22,23). Therefore,
single animal model is insufficient to elucidate the patho-
enesis of HCM caused by a diverse array of mutations.
Expression of transgene (human) cTnT in the back-
round of endogenous cTnT (mouse) could confound the
ffect of the mutant transgene protein. However, we have
reviously shown that expression of wild-type transgene
TnT in the mouse heart did not induce discernible histo-
ogic or echocardiographic phenotypes (8). With regard to
he potential background effects of the regulator protein, we
ncluded control groups composed of transgenic mice ex-
ressing only the regulator protein (GLp65) and bigenic
ice treated with a placebo only. We detected no discern-
ble phenotype in any of the control groups. Moreover,
revious studies have shown that the tripartite regulator
rotein is inactive when not bound to mifepristone
6,24,25). Finally, with regard to the potential confounding
ffects of the administration of mifepristone, we injected
ifepristone in NTG mice and detected no significant effect
n cardiac structure or function. These precautions further
trengthen our conclusions that the observed functional,
olecular, and histologic changes reflect the direct effects of
nduced expression of the mutant cTnT-Q92 transgene
rotein in the heart.
In conclusion, we describe a switch on–switch off bigenic
ouse model in which expression of cTnT-Q92, responsi-
le for human HCM, could be turned on and off as needed.
he results show that the established cardiac phenotypes in
CM are not permanent and could be reversed upon
urning off expression of the mutant protein. The findings
lso indicate that the initial phenotype induced by the
TnT-Q92 is enhanced myocardial systolic function fol-
owed by changes in activation of signaling molecules
mplicated in cell organization and myocyte function, fol-
owed by interstitial fibrosis. These findings provoke pursu-
ng specific therapies directed at correcting the underlying
he genetic defect in HCM.
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